Apolipoprotein ε4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 28, Issue 2, 2012, Pages 443-458

  Darreh Shori, Taher ^a   Siawesh, Manar ^a   Mousavi, Malahat ^a   Andreasen, Niels ^b   Nordberg, Agneta ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acetylcholinesterase; Alzheimer's disease; apolipoprotein 4 genotype; central cholinergic system; cutyrylcholinesterase K variant; pharmacogenetic

Indexed keywords

APOLIPOPROTEIN E4; CHOLINESTERASE;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; ENZYME ANALYSIS; FEMALE; GENOTYPE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; MINI MENTAL STATE EXAMINATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS;

EID: 84856992257     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-111088     Document Type: Article

References (70)

1. Ghebremedhin E, Thal DR, Schultz C, Braak H (2002) Age-dependent association between butyrylcholinesterase K-variant and Alzheimer disease-related neuropathology in human brains. Neurosci Lett 320, 25-28. (Pubitemid 34159268)
2. Holmes C, Ballard C, Lehmann D, David Smith A, Beaumont H, Day IN, NadeemKhan M, Lovestone S, McCulley M, Mor-ris CM, Munoz DG, O'Brien K, Russ C, Del Ser T, Warden D (2005) RateofprogressionofcognitivedeclineinAlzheimer's disease: Effect of butyrylcholinesterase K gene variation. J Neurol Neurosurg Psychiatry 76, 640-643. (Pubitemid 40569672)
3. Lehmann DJ, Johnston C, Smith AD (1997) Synergy between the genes for butyrylcholinesterase K variant and apolipopro-teinE4in late-onset confirmed Alzheimer's disease. Hum Mol Genet 6, 1933-1936. (Pubitemid 27460370)
4. Lehmann DJ, Nagy Z, Litchfield S, Borja MC, Smith AD (2000) Association of butyrylcholinesterase K variant with cholinesterase-positive neuritic plaques in the temporal cortex in late-onset Alzheimer's disease. Hum Genet 106, 447-452. (Pubitemid 30237513)
5. McIlroy SP, Crawford VL, Dynan KB, McGleenon BM, Vahidassr MD, Lawson JT, Passmore AP (2000) Butyryl-cholinesterase K variant is genetically associated with late onset Alzheimer's disease in Northern Ireland. J Med Genet 37, 182-185. (Pubitemid 30245911)
6. Perry E, McKeith I, Ballard C (2003) Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies. Neurology 60, 1852-1853. (Pubitemid 36737093)
7. Russ C, Powell J, Lovestone S, Holmes C (1998) K variant of butyrycholinesterase and late-onset Alzheimer's disease. Lance 351, 881. (Pubitemid 28121183)
8. Tasker A, Perry EK, Ballard CG (2005) Butyrylcholine-sterase: Impact on symptoms and progression of cognitive impairment. Expert Rev Neurother 5, 101-106. (Pubitemid 40127690)
9. Wiebusch H, Poirier J, Sevigny P, Schappert K (1999) Further evidence forasynergistic association between APOE epsilon4 and BCHE-K in confirmed Alzheimer's disease. Hum Genet 104, 158-163. (Pubitemid 29123608)
10. Yamada M, Sodeyama N, Itoh Y, Suematsu N, Otomo E, Matsushita M, Mizusawa H (1998) Butyrylcholinesterase K variant and cerebral amyloid angiopathy. Stroke 29, 2488-2490. (Pubitemid 28543995)
11. Darreh-Shori T, Brimijoin S, Kadir A, Almkvist O, Nordberg A (2006) Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism. Neurobiol Dis 24, 326-333. (Pubitemid 44572751)
12. Darreh-Shori T, Modiri N, Blennow K, Baza S, Kamil C, Ahmed H, Andreasen N, Nordberg A (2011) The apolipopro-tein E epsilon4 allele plays pathological roles in AD through high protein expression and interaction with butyryl-cholinesterase. Neurobiol Aging 32, 1236-1248.
13. Ferris S, Nordberg A, Soininen H, Darreh-Shori T, Lane R (2009) Progression from mild cognitive impairment to Alzheimer's disease: Effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment. Pharmacogenet Genomics 19, 635-646.
14. Lane R, Feldman HH, Meyer J, He Y, Ferris SH, Nordberg A, Darreh-Shori T, Soininen H, Pirttila T, Farlow MR, Sfikas N, Ballard C, Greig NH (2008) Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. Pharmacogenet Genomics 18, 289-298. (Pubitemid 351367522)
15. Darvesh S, Grantham DL, Hopkins DA (1998) Distribution of butyrylcholinesterase in the human amygdala and hippocam-pal formation. J Comp Neurol 393, 374-390. (Pubitemid 28164592)
16. Darvesh S, Hopkins DA (2003) Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus. J Comp Neurol 463, 25-43. (Pubitemid 36835411)
17. Mesulam M, Guillozet A, Shaw P, Quinn B (2002) Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis 9, 88-93. (Pubitemid 34174568)
18. Mesulam MM, Guillozet A, Shaw P, Levey A, Duysen EG, Lockridge O (2002) Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyryl-cholinesterase to hydrolyze acetylcholine. Neuroscience 110, 627-639. (Pubitemid 34270534)
19. Xie W, Stribley JA, Chatonnet A, Wilder PJ, Rizzino A, McComb RD, Taylor P, Hinrichs SH, Lockridge O (2000) Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetyl-cholinesterase. J Pharmacol Exp Ther 293, 896-902. (Pubitemid 30417856)
20. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, PerryRH (1978) Correlation ofcholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 2, 1457-1459. (Pubitemid 9061468)
21. Garry PJ, Dietz AA, Lubrano T, Ford PC, James K, Rubinstein HM (1976) New allele at cholinesterase locus 1. J Med Genet 13, 38-42.
22. Rubinstein HM, Dietz AA, Lubrano T (1978) E1k, another quantitative variant at cholinesterase locus 1. J Med Genet 15, 27-29. (Pubitemid 8273803)
23. Whittaker M, Britten JJ (1987) E1h, a new allele at cholinesterase locus 1. Hum Hered 37, 54-58. (Pubitemid 17019977)
24. Bartels CF, James K, La Du BN (1992) DNA mutations associated with the human butyrylcholinesterase J-variant. Am J Hum Genet 50, 1104-1114.
25. La Du BN, Bartels CF, Nogueira CP, Hajra A, Lightstone H, Van der Spek A, Lockridge O (1990) Phenotypic and molecular biological analysis of human butyrylcholinesterase variants. Clin Biochem 23, 423-431. (Pubitemid 20331358)
26. Bartels CF, Jensen FS, Lockridge O, van der Spek AF, Rubinstein HM, Lubrano T, La Du BN (1992) DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet 50, 1086-1103.
27. Evans RT, Wardell J (1984) On the identification and frequency of the J and K cholinesterase phenotypes in a Caucasian population. J Med Genet 21, 99-102. (Pubitemid 14155245)
28. Whittaker M, Britten JJ (1985) Plasma cholinesterase variants. Family studiesof the E1k gene. Hum Hered 35, 364-368. (Pubitemid 15250273)
29. Darreh-Shori T, Almkvist O, Guan ZZ, Garlind A, Strandberg B, Svensson AL, Soreq H, Hellstrom-Lindahl E, Nordberg A (2002) Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 59, 563-572. (Pubitemid 34919991)
30. Giacobini E, Spiegel R, Enz A, Veroff AE, Cutler NR (2002) Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: Correlation with cognitive benefit. J Neural Transm 109, 1053-1065. (Pubitemid 34762344)
31. O'Brien KK, Saxby BK, Ballard CG, Grace J, Harrington F, Ford GA, O'Brien JT, Swan AG, Fairbairn AF, Wesnes K, del Ser T, Edwardson JA, Morris CM, McKeith IG (2003) Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics 13, 231-239. (Pubitemid 36543396)
32. Alcantara VM, Chautard-Freire-Maia EA, Scartezini M, Cerci MS, Braun-Prado K, Picheth G (2002) Butyryl-cholinesterase activity and risk factors for coronary artery disease. Scand J Clin Lab Invest 62, 399-404.
33. Alcantara VM, Oliveira LC, Rea RR, Suplicy HL, Chautard-Freire-Maia EA (2005) Butyrylcholinesterase activity and metabolic syndrome in obese patients. Clin Chem Lab Med 43, 285-288.
34. Matte C, Durigon E, Stefanello FM, Cipriani F, Wajner M, Wyse AT (2006) Folic acid pretreatment prevents the reduction of Na (+), K (+)-ATPase and butyrylcholinesterase activities in rats subjected to acute hyperhomocysteinemia. Int J Dev Neurosci 24, 3-8. (Pubitemid 43287940)
35. Valle A, O'Connor DT, Taylor P, Zhu G, Montgomery GW, Slagboom PE, Martin NG, Whitfield JB (2006) Butyryl-cholinesterase: Association with the metabolic syndrome and identification of 2 gene loci affecting activity. Clin Chem 52, 1014-1020. (Pubitemid 43794411)
36. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report ofthe NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944. (Pubitemid 14076461)
37. Darreh-Shori T, Meurling L, Pettersson T, Hugosson K, Hellstrom-Lindahl E, Andreasen N, Minthon L, Nordberg A (2006) Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment. J Neural Transm 113, 1791-1801. (Pubitemid 44657676)
38. Darreh-Shori T, Kadir A, Almkvist O, Grut M, Wall A, Blomquist G, Eriksson B, Langstrom B, Nordberg A (2008) Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galan-tamine. Neurobiol Aging 29, 168-184.
39. Darreh-Shori T, Forsberg A, Modiri N, Andreasen N, Blennow K, Kamil C, Ahmed H, Almkvist O, Langstrom B, Nordberg A (2010) Differential levelsof apolipoprotein E and butyrylcholinesterase show strong association with pathological signsof Alzheimer's disease in the brain in vivo. Neurobiol Aging, doi:10.1016/j.neurobiolaging.2010.04.028.
40. Raygani AV, Zahrai M, Soltanzadeh A, Doosti M, Javadi E, Pourmotabbed T (2004) Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer's disease. Neurosci Lett 371, 142-146. (Pubitemid 39445362)
41. Hiltunen M, Mannermaa A, Helisalmi S, Koivisto A, Lehtovirta M, Ryynanen M, Riekkinen P Sr, Soininen H (1998) Butyrylcholinesterase Kvariant and apolipoprotein E4 genes do not act in synergy in Finnish late-onset Alzheimer's disease patients. Neurosci Lett 250, 69-71. (Pubitemid 28341779)
42. Ki CS, Na DL, Kim JW, Kim HJ, Kim DK, Yoon BK (1999) No association between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer's disease. Am J Med Genet 88, 113-115. (Pubitemid 29156444)
43. Kim KW, Jhoo JH, Lee JH, Lee KU, Lee DY, Youn JC, Youn JY, Woo JI (2001) Neither the butyrylcholinesterase K variant nor transferrin C2 variant confers a risk for Alzheimer's disease in Koreans. J Neural Transm 108, 1159-1166. (Pubitemid 33022765)
44. Lee DW, Liu HC, Liu TY, Chi CW, HongCJ (2000)Noassoci-ation between butyrylcholinesterase K-variant and Alzheimer disease in Chinese. Am J Med Genet 96, 167-169. (Pubitemid 30180856)
45. Singleton AB, Smith G, Gibson AM, Woodward R, Perry RH, Ince PG, Edwardson JA, Morris CM (1998) No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer's disease. Hum Mol Genet 7, 937-939. (Pubitemid 28221259)
46. Yamamoto Y, Yasuda M, Mori E, Maeda K (1999) Failure to confirm a synergistic effect between the K-variant of the butyrylcholinesterase gene and the epsilon4 allele of the apolipoprotein gene in Japanese patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry 67, 94-96. (Pubitemid 29278335)
47. Darreh-Shori T, Hellstrom-Lindahl E, Flores-Flores C, Guan ZZ, Soreq H, Nordberg A (2004) Long-lasting acetyl-cholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients. J Neurochem 88, 1102-1113. (Pubitemid 38280678)
48. Kadir A, Darreh-Shori T, Almkvist O, Wall A, Grut M, Strandberg B, Ringheim A, Eriksson B, Blomquist G, Langstrom B, Nordberg A (2008) PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. Neurobiol Aging 29, 1204-1217. (Pubitemid 351822413)
49. Babaoglu MO, Ocal T, Bayar B, Kayaalp SO, Bozkurt A (2004) Frequency and enzyme activity of the butyryl-cholinesterase K-variant in a Turkish population. Eur J Clin Pharmacol 59, 875-877. (Pubitemid 38333677)
50. Maetzler W, Keller S, Michelis J, Koehler N, Stransky E, Becker C, Schulte C, Melms A, Gasser T, Berg D (2009) No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases. Neurobiol Dis 35, 296-301.
51. Mosimann UP, McKeith IG (2003) Dementia with Lewy bodies-diagnosis and treatment. Swiss Med Wkly 133, 131-142.
52. Podoly E, Shalev DE, Shenhar-Tsarfaty S, Bennett ER, Ben Assayag E, Wilgus H, Livnah O, Soreq H (2009) The butyryl-cholinesterase K variant confers structurally derived risks for Alzheimer pathology. J Biol Chem 284, 17170-17179.
53. Simeon-Rudolf V, Kovarik Z, Skrinjaric-Spoljar M, Evans RT (1999) An explanation for the different inhibitory characteristics of human serum butyrylcholinesterase phenotypes deriving from inhibition of atypical heterozygotes. Chem Biol Interact 119-120, 159-164. (Pubitemid 29278549)
54. Darreh-Shori T, Modiri N, Nordberg A (2009) ApoE and amyloid beta deflate the cholinergic neurotransmission by boosting the activity and stability of cholinesterases in the brain. Alzheimers Dement 5, P305.
55. Masson P (1989) A naturally occurring molecular form of human plasma cholinesterase is an albumin conjugate. Biochim Biophys Acta 998, 258-266. (Pubitemid 19248422)
56. Darreh-Shori T, Modiri N, Lahaut P, Nordberg A (2009) Apolipoprotein E and Butyrylcholinesterase synergistically promote Ab peptides oligomerization. Alzheimers Dement 5, P225.
57. Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, Bu G, Mennerick S, HoltzmanDM (2008) Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron 58, 42-51. (Pubitemid 351467029)
58. Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM (2005) Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 48, 913-922. (Pubitemid 41814696)
59. Alvarez-Arcaya A, Combarros O, Llorca J, Sanchez-Guerra M, Berciano J, Fernandez-Viadero C, Pena N (2000) The butyrylcholinesterase K variant is a protective factor for sporadic Alzheimer's disease in women. Acta Neurol Scand 102, 350-353.
60. Lehmann DJ, Williams J, McBroom J, Smith AD (2001) Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alzheimer's disease and to identify high-risk subgroups. Neuroscience 108, 541-554. (Pubitemid 33660714)
61. Chen VP, Xie HQ, Chan WK, Leung KW, Chan GK, Choi RC, Bon S, Massoulie J, Tsim KW (2010) The PRiMA-linked cholinesterase tetramers are assembled from homodimers: Hybrid molecules composed of acetylcholinesterase and butyrylcholinesterase dimers are up-regulated during development of chicken brain. J Biol Chem 285, 27265-27278.
62. Garcia-Ayllon MS, Saez-Valero J, Munoz-Delgado E, Vidal CJ (2001) Identification of hybrid cholinesterase forms consisting of acetyl- and butyrylcholinesterase subunits in human glioma. Neuroscience 107, 199-208. (Pubitemid 33145342)
63. Berson A, Knobloch M, Hanan M, Diamant S, Sharoni M, Schuppli D, Geyer BC, Ravid R, Mor TS, Nitsch RM, Soreq H (2008) Changes in readthrough acetylcholinesterase expression modulate amyloid-beta pathology. Brain 131, 109-119.
64. Diamant S, Podoly E, Friedler A, Ligumsky H, Livnah O, Soreq H (2006) Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc Natl Acad Sci U S A 103, 8628-8633. (Pubitemid 43878071)
65. Geula C, Greenberg BD, MesulamMM (1994) Cholinesterase activity in the plaques, tangles and angiopathy of Alzheimer's disease does not emanate from amyloid. Brain Res 644, 327-330. (Pubitemid 24127990)
66. Geula C, Mesulam MM (1995) Cholinesterases and the pathology of Alzheimer disease. Alzheimer Dis Assoc Disord 9 (Suppl 2), 23-28.
67. Guillozet AL, Smiley JF, Mash DC, Mesulam MM (1997) Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 42, 909-918. (Pubitemid 28008422)
68. Mesulam M, Carson K, Price B, Geula C (1992) Cholinesterases in the amyloid angiopathy of Alzheimer's disease. Ann Neurol 31, 565-569.
69. Mesulam MM, Geula C (1994) Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 36, 722-727. (Pubitemid 24337630)
70. Darreh-Shori T, Bälter M, Siawesh M, Nordberg A (2011) Impact of Butyrylcholinesterase K genotype on glial and proinflammatory markersinCSF of patients with Alzheimer's disease. Alzheimers Dement 7, S407.